

World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2024 May 27; 16(5): 1218-1484



EDITORIAL

- 1218 Is there a place for endoscopic management in post-cholecystectomy iatrogenic bile duct injuries?
Cai HQ, Pan GQ, Luan SJ, Wang J, Jiao Y
- 1223 Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how
Manojlovic N, Savic G, Manojlovic S
- 1231 Clinical diagnostic advances in intestinal anastomotic techniques: Hand suturing, stapling, and compression devices
Lee AY, Cho JY
- 1235 Surgical treatment of inflammatory bowel disease: From the gastroenterologist's stand-point
Triantafyllidis JK
- 1255 Management of early oesophageal cancer: An overview
Calpin GG, Davey MG, Donlon NE

ORIGINAL ARTICLE**Case Control Study**

- 1259 Clinical characteristics and risk factors of post-operative intestinal flora disorder following laparoscopic colonic surgery: A propensity-score-matching analysis
Li GB, Wang CT, Zhang X, Qiu XY, Chen WJ, Lu JY, Xu L, Wu B, Xiao Y, Lin GL

Retrospective Cohort Study

- 1271 Comparing short-term outcomes of robot-assisted and conventional laparoscopic total mesorectal excision surgery for rectal cancer in elderly patients
Yang H, Yang G, Wu WY, Wang F, Yao XQ, Wu XY
- 1280 Robotic vs laparoscopic abdominoperineal resection for rectal cancer: A propensity score matching cohort study and meta-analysis
Song L, Xu WQ, Wei ZQ, Tang G
- 1291 Preoperative prognostic nutritional index predicts long-term outcomes of patients with ampullary adenocarcinoma after curative pancreatoduodenectomy
Sun CY, Zhang XJ, Li Z, Fei H, Li ZF, Zhao DB
- 1301 Development and validation of a predictive model for acute-on-chronic liver failure after transjugular intrahepatic portosystemic shunt
Zhang W, Jin YN, Sun C, Zhang XF, Li RQ, Yin Q, Chen JJ, Zhuge YZ

Retrospective Study

- 1311 Evaluating the use of three-dimensional reconstruction visualization technology for precise laparoscopic resection in gastroesophageal junction cancer
Guo D, Zhu XY, Han S, Liu YS, Cui DP
- 1320 Comparative observation of the effectiveness and safety of remimazolam besylate versus dexmedetomidine in gastrointestinal surgery in obese patients
Deng YF, Jiang XR, Feng ZG
- 1328 *GLI1* and *PTTG1* expression in colorectal carcinoma patients undergoing radical surgery and their correlation with lymph node metastasis
Cao F, Chen YY, Wang HC
- 1336 Clinical feasibility of laparoscopic left lateral segment liver resection with magnetic anchor technique: The first clinical study from China
Zhang MM, Bai JG, Zhang D, Tao J, Geng ZM, Li ZQ, Ren YX, Zhang YH, Lyu Y, Yan XP
- 1344 Prognostic prediction model of colorectal cancer based on preoperative serum tumor markers
Diao YH, Rao SQ, Shu XP, Cheng Y, Tan C, Wang LJ, Peng D
- 1354 Predictors of complications after prophylactic ileostomy reversal for rectal cancer: A retrospective study
Lv Q, Shu XP, Peng D, Li SQ, Xiang Z
- 1363 Effect of the extrahepatic bile duct anatomy on choledocholithiasis and its clinical significance
Cao Z, Zhou J, Wei L, He HY, Li J

Randomized Controlled Trial

- 1371 Effects of oral probiotics on inflammation and intestinal function in adult patients after appendectomy: Randomized controlled trial
Lan K, Zeng KR, Zhong FR, Tu SJ, Luo JL, Shu SL, Peng XF, Yang H, Lu K
- 1377 Clinical study on microscopic syndrome differentiation and traditional Chinese medicine treatment for liver stomach disharmony in chronic gastritis
Bai CY, Tian W, Zhang Q

Basic Study

- 1385 Establishment of acquired tracheoesophageal fistula using a modified magnetic compression technique in rabbits and its postmodeling evaluation
Meng H, Nan FY, Kou N, Hong QY, Lv MS, Li JB, Zhang BJ, Zou H, Li L, Wang HW
- 1395 Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer
Yu QX, Fu PY, Zhang C, Li L, Huang WT

META-ANALYSIS

- 1407 Evaluating effectiveness and safety of combined percutaneous transhepatic gallbladder drainage and laparoscopic cholecystectomy in acute cholecystitis patients: Meta-analysis
Li Y, Xiao WK, Li XJ, Dong HY
- 1420 Prognostic factors associated with gastrointestinal dysfunction after gastrointestinal tumor surgery: A meta-analysis
Song J, Zhou C, Zhang T

CASE REPORT

- 1430 Multi-modal imaging for the diagnosis of spontaneous visceral artery dissection: A case report
Pu Y, Luo Y
- 1436 Metastatic stomach lymphoepithelioma-like carcinoma and immune checkpoint inhibitor therapy: A case report
Chen GF, Wang J, Yan Y, Xu S, Chen J
- 1443 Treatment of anastomotic stricture after rectal cancer operation by magnetic compression technique: A case report
Zhang MM, Sha HC, Xue HR, Qin YF, Dong FF, Zhang L, Lyu Y, Yan XP
- 1449 Neuroendocrine carcinoma of the common hepatic duct coexisting with distal cholangiocarcinoma: A case report and review of literature
Chen F, Li WW, Mo JF, Chen MJ, Wang SH, Yang SY, Song ZW
- 1461 Hem-o-lok clip migration to duodenal bulb post-cholecystectomy: A case report
Liu HY, Yin AH, Wei Z

LETTER TO THE EDITOR

- 1467 Resection and reconstruction in high-grade pancreatic head injuries
Krige J, Jonas E, Nicol AJ, Navsaria PH
- 1470 Should we perform decompressive laparotomy during severe acute pancreatitis with intra-abdominal hypertension below 25 mmHg: Only the gut knows
Vieille T, Crotet M, Turco C, Monasterolo P, Winiszewski H, Piton G
- 1474 Primary repair of esophageal atresia Gross type C *via* thoracoscopic magnetic compression anastomosis: Is it the best option?
Pérez-Bertólez S, Godoy-Lenz J
- 1482 Exploring predictive markers for liver failure post-hepatectomy in hepatocellular carcinoma patients
Zhang SY, Ma XJ, Zhu XX, Cai N

ABOUT COVER

Peer reviewer of *World Journal of Gastrointestinal Surgery*, Ramesh Kumar, MBBS, MD, Additional Professor, Teacher, Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, Bihar, India. docrameshkr@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Surgery* (*WJGS, World J Gastrointest Surg*) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, *etc.*

INDEXING/ABSTRACTING

The *WJGS* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJGS* as 2.0; IF without journal self cites: 1.9; 5-year IF: 2.2; Journal Citation Indicator: 0.52; Ranking: 113 among 212 journals in surgery; Quartile category: Q3; Ranking: 81 among 93 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Zi-Hang Xu, Production Department Director: Xiang Li, Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Surgery

ISSN

ISSN 1948-9366 (online)

LAUNCH DATE

November 30, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Peter Schemmer

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-9366/editorialboard.htm>

PUBLICATION DATE

May 27, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.fcpublishing.com>



Metastatic stomach lymphoepithelioma-like carcinoma and immune checkpoint inhibitor therapy: A case report

Guo-Feng Chen, Jun Wang, Yu Yan, Song Xu, Jian Chen

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade C

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Jabbarpour Z, United Kingdom

Received: January 4, 2024

Revised: April 10, 2024

Accepted: April 22, 2024

Published online: May 27, 2024



Guo-Feng Chen, Jun Wang, Jian Chen, Department of Gastroenterology Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

Jun Wang, Jian Chen, Cancer Center, Zhejiang University, Hangzhou 310000, Zhejiang Province, China

Yu Yan, Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

Song Xu, Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

Co-first authors: Guo-Feng Chen and Jun Wang.

Corresponding author: Jian Chen, MD, PhD, Director, Department of Gastroenterology Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310000, Zhejiang Province, China. zrchenjian@zju.edu.cn

Abstract

BACKGROUND

Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare type of non-small-cell lung cancer. Stomach lymphoepithelioma-like carcinoma (LELC) metastasis secondary to PLELC has not been reported recently.

CASE SUMMARY

A 64-year-old female was admitted to our hospital for a regular gastroscopy examination with a 6-year history of surgical resection for left PLELC. Positron emission tomography/computed tomography suggested high accumulation of 18F-fludeoxyglucose in the gastric cardia region. Upper gastrointestinal endoscopy confirmed a large mass at the stomach fundus. Immunohistochemistry (IHC) of the biopsy suggested metastatic stomach LELC. Proximal gastrectomy showed that this 6.5 cm × 5.0 cm mass was located in the stomach fundus near the cardia. Histopathological examination showed a poorly differentiated carcinoma with prominent lymphoplasmacytic infiltration. IHC demonstrated that the tumor was positive for CK (AE1/AE3), p63, p40, p53, Ki-67 (70%), and EGFR (3+) and negative for CK7, CK20, Her2, and CD10. *In situ* hybridization analysis showed positive staining Epstein-Barr virus-encoded RNA. Tumor programmed cell death ligand 1 (PD-L1) expression score was 98%, and the combined positive score was

100, with no evidence of microsatellite instability. Thus, the patient was unequivocally diagnosed with metastatic stomach LELC secondary to pulmonary LELC. After discharge, this patient underwent PD-1 inhibitor treatment (toripalimab, 240 mg) every 3 wk for ten cycles, and she has had no tumor recurrence.

CONCLUSION

For gastric LELC metastasis, PD-1 inhibitor therapy could become a new therapeutic approach, though there is still no evidence from large data sets to support this.

Key Words: Stomach neoplasm; Pulmonary lymphoepithelioma-like carcinoma; Metastasis; Immune checkpoint inhibitor; Case report

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare type of non-small-cell lung cancer. Stomach lymphoepithelioma-like carcinoma (LELC) metastasis secondary to PLELC has not been reported recently. We present a 64-year-old female patient who was admitted to our hospital for a regular gastroscopy examination with a 6-year history of surgical resection for left PLELC. After proximal gastrectomy, histopathological examination showed a poorly differentiated carcinoma with prominent lymphoplasmacytic infiltration, suggesting stomach LELC metastasis. Tumor programmed cell death ligand 1 (PD-L1) expression showed a tumor proportion score of 98% and a combined positive score of 100. After discharge, this patient underwent PD-1 inhibitor treatment for ten cycles and has not experienced tumor recurrence. These findings suggest that for gastric LELC metastasis, PD-1 inhibitor therapy could become a potential therapeutic approach.

Citation: Chen GF, Wang J, Yan Y, Xu S, Chen J. Metastatic stomach lymphoepithelioma-like carcinoma and immune checkpoint inhibitor therapy: A case report. *World J Gastrointest Surg* 2024; 16(5): 1436-1442

URL: <https://www.wjgnet.com/1948-9366/full/v16/i5/1436.htm>

DOI: <https://dx.doi.org/10.4240/wjgs.v16.i5.1436>

INTRODUCTION

Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare type of non-small cell lung cancer that tends to occur in young, nonsmoking, and Asian populations[1]. It has unique clinical and pathological features that are similar to those of undifferentiated nasopharyngeal carcinoma[2,3]. PLELC is characterized by Epstein-Barr virus (EBV) infection. According to whole-exome sequencing, targeted deep sequencing and single-nucleotide polymorphism arrays, the genetic lesions affect several critical pathways, including the NF- κ B, JAK/STAT, and cell cycle pathways[4]. Along with conventional surgical resection, immunotherapy has become a focus of attention[5,6]. Although lymphoepithelioma-like carcinoma (LELC) metastasis has been reported, including subcutaneous[7], endotracheal[8], and lung door and mediastinal lymph nodes[9], stomach LELC secondary to PLELC has not been reported recently, nor have treatments for it.

CASE PRESENTATION

Chief complaints

A 64-year-old female patient was admitted to our hospital for a regular gastroscopy examination.

History of present illness

There is no history of present illness.

History of past illness

The patient had a 6-year history of surgical resection for left PLELC. She underwent four cycles of gemcitabine plus cisplatin chemotherapy, four cycles of pemetrexed plus carboplatin chemotherapy, and 30 cycles of radiotherapy (Figure 1).

Personal and family history

The patient denied any chronic medical history, such as hypertension, diabetes, heart disease, or tobacco or alcohol (illicit drug) use.

Physical examination

On physical examination, the patient reported no obvious discomfort.




Figure 1 Timeline of history of past illness, initial diagnosis, surgical intervention, postoperative adjuvant therapy, and follow-up period. PET-CT: Positron emission tomography/computed tomography; PD-1: programmed cell death 1.

Laboratory examinations

Laboratory findings included increased levels of tumor markers, such as carbohydrate antigen 125 (CA125) (36.9 U/mL; reference range, < 35 U/mL) and CA211 (5.9 ng/mL; reference range, < 5 ng/mL). A stool occult blood test was positive.

Imaging examinations

Gastroscopy revealed a space-occupying lesion in the cardia/fundus region of the stomach. A whole-abdominal contrast-enhanced computed tomography (CT) scan showed an irregular mass in the gastric cardia. Positron emission tomography/CT was also performed, which suggested high levels of 18F-fludeoxyglucose accumulation in the gastric cardia region (a maximum standardized uptake value of 20.03), indicating malignant tumors (Figure 2). Upper gastrointestinal endoscopy further confirmed a large mass of about 5 cm × 4 cm at the stomach fundus, and this submucosal bulge broke into the stomach cavity (Figure 3A). According to the immunohistochemistry (IHC) of the biopsy, the pathological diagnosis was a metastatic stomach lymphoepithelioma-like carcinoma.

FINAL DIAGNOSIS

Based on all the findings, the patient was diagnosed with metastatic LELC of the stomach.

TREATMENT

Based on the above diagnosis, we performed laparoscopic exploration, proximal gastrectomy, and double-channel anastomosis between the esophagus, residual stomach, and jejunum. Surgical resection of the tumor revealed a large mass located in the stomach fundus near the cardia, presenting as a type of ulcer infiltrate with a size of 6.0 cm × 5.0 cm (Figure 3B). Pathology after surgery showed a poorly differentiated carcinoma of the gastric fundus of 6.5 cm × 5.0 cm. Only one perigastric LN showed positive metastasis (1/24). Histopathological examination by hematoxylin and eosin staining of the stomach tumor sections showed a poorly differentiated carcinoma with prominent lymphoplasmacytic infiltration (Figure 4A). IHC analysis demonstrated that the tumor was positive for CK (AE1/AE3), p63, p40, p53, Ki-67 (70%), and EGFR (3+) and negative for CK7, CK20, Her2, Muc-5AC, Muc-6, Muc-2, and CD10. *In situ* hybridization showed positive staining for EBV -encoded RNA (Figure 4B). Moreover, the ICH results of the positive LN were consistent with those of the stomach lesions. When we analyzed tumor programmed cell death ligand 1 (PD-L1) expression, we found a tumor proportion score of 98% and a combined positive score of 100, with no evidence of microsatellite instability. The pathological findings were consistent with those reported for pulmonary LELC. Thus, the patient was unequivocally diagnosed with stomach LELC metastatic secondary to pulmonary LELC. After 16 d of routine treatment following gastrectomy, the patient was discharged.

OUTCOME AND FOLLOW-UP

The patient underwent immune checkpoint inhibitor (ICI) treatment with a PD-1 inhibitor (toripalimab, 240 mg, intravenous drip) every 3 wk after discharge (September 6, 2022). On outpatient follow-up, the patient stayed on schedule for ten cycles of PD-1 inhibitor treatment. So far, no adverse events and no tumor recurrence have occurred.




Figure 2 Positron emission tomography/computed tomography showing high accumulation of ^{18}F -fluorodeoxyglucose in the gastric cardia region. A maximum standardized uptake value of 20.03.

DISCUSSION

Pulmonary LELC is a rare type of non-small-cell lung cancer. Cases of pulmonary or metastatic LELC have been reported recently, but to our knowledge, this is the first report of stomach LELC metastasis secondary to a pulmonary tumor.

The most common approach for treating LELC is multimodal therapy. The expression of PD-1/PD-L1 may be related to the prognosis of LELC[10]. Growing evidence shows that ICIs are effective against pulmonary LELC[5]. One study reviewed 36 patients with PLELC treated with PD-1/PD-L1 inhibitors[6]. The objective response rate of all 36 patients was 57.6%, and the patients with higher PD-L1 expression were more likely to have a tumor response. In another study in which patients received multiple treatments that were ineffective, including surgery, chemotherapy and radiotherapy, ICIs proved to be a feasible option[11]. The efficacy of ICI therapy in patients with metastatic stomach LELC is unknown.

In one metastasis study[9], the patient was diagnosed with PLELC as well as metastasis to the mediastinal lymph nodes and liver. After five cycles of nivolumab, the tumor and the lesions in the liver became smaller. The values of CYFRA21-1 and NSE dramatically decreased. Another study found advanced thymic LELC with bone marrow metastases[12]. This patient responded well to toripalimab after 10 months of therapy. Based on the above evidence, we gave our patient a PD-1 inhibitor (toripalimab, 240 mg, intravenous drip) every 3 wk after discharge for ten cycles, with no radiographical evidence of tumor recurrence.

For this case, two questions are worth considering. First, what is the pathway through which lung cancer metastasizes to the stomach? Although gastric metastasis from lung cancer is rare, it can spread to the gastrointestinal tract through hematogenous and lymphatic routes[13]. Based on the findings in the positive LN, which was consistent with those in the stomach lesions, we believe that this patient's gastric metastasis was through the lymphatic pathway. Second, do we have better treatment options, such as PD-1 inhibitor treatment, before surgery? Because of the growing evidence about PD-1




Figure 3 Upper endoscopy and surgical resection. A: The presence of a large mass of about 5 cm × 4 cm at the stomach fundus was confirmed by upper endoscopy; B: Surgical resection of the tumor revealed a large mass located in the stomach fundus near the cardia, showing a type of ulcer infiltrate measuring 6 cm × 5 cm.




Figure 4 Hematoxylin and eosin staining and *in situ* hybridization. A: Histopathological examination of a stomach tumor section by hematoxylin and eosin staining, showing poorly differentiated carcinoma with prominent lymphoplasmacytic infiltration; B: *In situ* hybridization analysis showing positive staining for Epstein-Barr virus-encoded RNA.

inhibitors in pulmonary or metastatic LELC, we may prioritize PD-1 inhibitors in later-stage cases, especially for patients who cannot undergo surgical resection.

In conclusion, the present case presents a rare type of stomach tumor secondary to pulmonary LELC. This case demonstrates the necessity of IHC for differential diagnosis. ICIs such as PD-1 inhibitors may play an important role in the treatment of metastatic LELC.

CONCLUSION

The case suggested that for metastatic gastric LELC, PD-1 inhibitor therapy can become a potential therapeutic approach. However, there is still a lack of evidence from large data and large samples to support this.

ACKNOWLEDGEMENTS

We greatly thank the Department of Gastroenterology Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, for providing technical advice.

FOOTNOTES

Author contributions: Chen GF and Wang J contributed equally to this work; Chen GF and Wang J wrote draft of the manuscript and participated in the patient's treatment; Xu S performed the gastroscopy and provided the images; Yan Y, as a pathologist, performed the histological findings; Chen J supervised the study, developed the concept and edited the paper; and all authors have approved the final version of the manuscript.

Supported by the Zhejiang Provincial Key Project of Research and Development, No. 2019C03043; National Natural Science Foundation of China, No. 82203452; Health Science and Technology Plan of Zhejiang Province, No. 2022RC165; and Clinical Research Fund of Zhejiang Medical Association, No. 2021ZYC-A68.

Informed consent statement: Informed written consent was obtained from the patients for the publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: China

ORCID number: Guo-Feng Chen [0000-0003-1927-088X](https://orcid.org/0000-0003-1927-088X); Jian Chen [0000-0002-2542-9669](https://orcid.org/0000-0002-2542-9669).

S-Editor: Chen YL

L-Editor: A

P-Editor: Xu ZH

REFERENCES

- 1 Sathirareuanchai S, Hirata K. Pulmonary Lymphoepithelioma-like Carcinoma. *Arch Pathol Lab Med* 2019; **143**: 1027-1030 [PMID: 30672338 DOI: [10.5858/arpa.2018-0149-RS](https://doi.org/10.5858/arpa.2018-0149-RS)]
- 2 Chen B, Zhang Y, Dai S, Zhou P, Luo W, Wang Z, Chen X, Cheng P, Zheng G, Ren J, Yang X, Li W. Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses. *Signal Transduct Target Ther* 2021; **6**: 6 [PMID: 33414372 DOI: [10.1038/s41392-020-00382-6](https://doi.org/10.1038/s41392-020-00382-6)]
- 3 Fan Y, Li C, Qin J, Lu H. Primary pulmonary lymphoepithelioma-like carcinoma. *Med Oncol* 2020; **37**: 20 [PMID: 32146584 DOI: [10.1007/s12032-020-1344-3](https://doi.org/10.1007/s12032-020-1344-3)]
- 4 Hong S, Liu D, Luo S, Fang W, Zhan J, Fu S, Zhang Y, Wu X, Zhou H, Chen X, Chen G, Zhang Z, Zheng Q, Li X, Chen J, Liu X, Lei M, Ye C, Wang J, Yang H, Xu X, Zhu S, Yang Y, Zhao Y, Zhou N, Zhao H, Huang Y, Zhang L, Wu K. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. *Nat Commun* 2019; **10**: 3108 [PMID: 31311932 DOI: [10.1038/s41467-019-10902-w](https://doi.org/10.1038/s41467-019-10902-w)]

- 5 **Archwamety A**, Ruangchira-Urai R, Akewanlop C, Korphaisarn K. Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review. *Thorac Cancer* 2022; **13**: 2539-2541 [PMID: 35830974 DOI: 10.1111/1759-7714.14580]
- 6 **Zhou N**, Tang H, Yu S, Lin Y, Wang Y. Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma. *Front Immunol* 2022; **13**: 1001414 [PMID: 36561745 DOI: 10.3389/fimmu.2022.1001414]
- 7 **Shima T**, Taniguchi K, Kobayashi Y, Kakimoto S, Fujio N, Uchiyama K. Clinical silence of pulmonary lymphoepithelioma-like carcinoma with subcutaneous metastasis: a case report. *World J Surg Oncol* 2019; **17**: 128 [PMID: 31340830 DOI: 10.1186/s12957-019-1671-z]
- 8 **Mlika M**, Hamdi B, Marghli A, El Mezni F. About a lymphoepithelioma-like carcinoma of the lung with an endotracheal localization. *Tunis Med* 2018; **96**: 451-453 [PMID: 30430492]
- 9 **Qiu ZX**, Zhou P, Wang K. Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report. *Oncotargets Ther* 2019; **12**: 8595-8600 [PMID: 31802895 DOI: 10.2147/OTT.S219512]
- 10 **Sha Z**, Wei Y, Gao T, Luo Y, Chen J, Li T, Hu L, Niu X, Lin Z, Lv W, Pei X. Clinical observation of pulmonary lymphoepithelioma-like carcinoma. *J Thorac Dis* 2021; **13**: 5683-5690 [PMID: 34795918 DOI: 10.21037/jtd-21-1369]
- 11 **Wu Z**, Xian X, Wang K, Cheng D, Li W, Chen B. Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma. *Front Oncol* 2021; **11**: 626566 [PMID: 33981599 DOI: 10.3389/fonc.2021.626566]
- 12 **Li YJ**, Li YW, Cui GH, Li SH, Deng YW, Lu D. Advanced thymic lymphoepithelioma-like carcinoma with bone marrow metastases treated by immunotherapy combined with antiangiogenesis therapy: a case report. *Anticancer Drugs* 2022; **33**: 686-690 [PMID: 35324515 DOI: 10.1097/CAD.0000000000001293]
- 13 **Tang D**, Lv J, Liu Z, Zhan S, Gao Y. Gastric Metastasis of Primary Lung Cancer: Case Report and Systematic Review With Pooled Analysis. *Front Oncol* 2022; **12**: 922016 [PMID: 35875072 DOI: 10.3389/fonc.2022.922016]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

